XMT-1592

XMT-1592 is an ADC created using our proprietary Dolasynthen platform – a customizable and homogeneous platform designed to precisely optimize an ADC for a given target, drug-to-antibody ratio (DAR) and antibody. XMT-1592 comprises the same proprietary NaPi2b antibody and potent auristatin DolaLock payload with controlled bystander effect as XMT-1536, with the additional features of site-specific bioconjugation, precise DAR and homogeneous DAR distribution. In preclinical studies, Dolasynthen ADCs show enhanced pharmacokinetics, higher tumor exposure, and greater efficacy compared to Dolaflexin ADCs. We initiated a Phase 1 dose escalation trial of XMT-1592 in patients with tumors likely to express NaPi2b in May 2020.

XMT-1592